Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals

NCT00001080 · clinicaltrials.gov ↗

NA

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped as of 4/23/97

Conditions

HIV Infections

Interventions

BIOLOGICAL: Influenza Virus Vaccine
BIOLOGICAL: Pneumococcal Vaccine, Polyvalent (23-valent)
DRUG: Lamivudine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)